Benjamin Mazaleyrat

Statistics

Publications

Citations

H-Index

Active since

2019

Affiliations

Benjamin Mazaleyrat is an author at Roche (France) specializing in cost-effectiveness analysis, cost-effectiveness modeling, and cost-utility analysis.

Publications per year

2019–2023

Publications

Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France

Sivignon Marine, Roze Stéphane, N. Plommet et al. · Journal of Medical Economics · 2020 · 17 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France

E. Clay, Olivier Cristeau, Romain Chafaie et al. · Journal of Market Access & Health Policy · 2019 · 16 citations · Full text

Pharmacy, Economics, Pharmacoeconomics +17

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France

L. Gaugain, Hélène Cawston, Coline Dubois de Gennes et al. · PLoS ONE · 2023 · 14 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

1–3 of 3